TGTX has not mentioned the "Fast Track" designation for MS as far as I know, and I don't know if it's even available for that indication.
The real question for TGTX's valuation is this - Will the FDA approve their cancer trials after TGTX arbitrarily scrapped the SPA, or will they make TGTX run another lengthy and costly trial before approval?
Market Data 
Markets 
AI
